tldrdailynews.com logo
Tag

Galleri

All articles tagged with #galleri

Testing the Promise: My Take on the Galleri Cancer Blood Test
health2 days ago

Testing the Promise: My Take on the Galleri Cancer Blood Test

A first-person look at Grail’s Galleri multi-cancer early detection blood test: the $824 home draw returned no cancer signal, but real-world results are mixed and medical groups remain cautious, with limited evidence of mortality benefit and concerns about false positives and missed cancers. While some see potential, experts emphasize that MRI scans or traditional symptom-driven screening remain more established, and readers are advised to discuss symptoms with a doctor and not rely on MCED tests as a sole screening tool.

via Business Insider|
#at-home-testing#cancer-screening#galleri
The bold promise of multi-cancer blood tests hits real-world limits
health1 month ago

The bold promise of multi-cancer blood tests hits real-world limits

Multi-cancer early detection (MCED) blood tests, including Galleri, promise to detect dozens of cancers from one blood sample, but few have robust randomized trial data; the NHS-backed Galleri trial failed to show improved outcomes in reducing late-stage cancers, and while tests boast high specificity, sensitivity varies and the risk of false positives can lead to anxiety and unnecessary follow-ups, leaving regulators and clinicians cautious until stronger evidence accumulates.

via Nature|
#cancer-screening#galleri#health
Grail stock slumps after NHS Galleri trial misses primary endpoint
healthcare1 month ago

Grail stock slumps after NHS Galleri trial misses primary endpoint

Grail's stock fell more than 45% after-hours after NHS-Galleri trial failed to meet its primary endpoint, showing no statistically significant reduction in later-stage cancers overall; however, a pre-specified group of 12 deadly cancers showed a favorable trend toward fewer stage III-IV cancers, with greater reductions in stage IV diagnoses across sequential screening rounds. The company will extend follow-up by 6-12 months to seek stronger effects, and it also reported 17% full-year revenue growth to $147.2 million, with U.S. Galleri revenue up 26% to $136.8 million.

via Fierce Biotech|
#clinical-trials#galleri#grail
Major UK Trial Undermines Promise of Galleri Multi-Cancer Blood Test
health1 month ago

Major UK Trial Undermines Promise of Galleri Multi-Cancer Blood Test

In a large UK trial of 142,000 adults over three years, Grail's Galleri multi-cancer blood test did not reduce late-stage cancers (stages 3–4), though researchers noted a secondary signal of fewer Stage 4 cancers; the test remains FDA-unapproved, is sold with limited insurer coverage, and Medicare coverage remains under legislative review.

via The New York Times|
#cancer-detection#clinical-trial#galleri
Grail's Galleri multi-cancer test misses primary endpoint in NHS study, fueling skepticism
biotech1 month ago

Grail's Galleri multi-cancer test misses primary endpoint in NHS study, fueling skepticism

Grail's Galleri blood test for early cancer detection failed to meet its primary endpoint in a large NHS-backed study, renewing questions about its clinical utility despite some detected benefits. Grail reported selling 185,000 tests in 2025 for $136.8 million, and its stock fell about 47% after hours following the setback.

via statnews.com|
#biotech#cancer-detection#diagnostics
Rush Launches Blood Test to Detect Over 50 Cancers Amid Industry Hesitation
health8 months ago

Rush Launches Blood Test to Detect Over 50 Cancers Amid Industry Hesitation

Rush University is now offering the Galleri blood test, which can detect over 50 types of cancer early by identifying cancer DNA in the bloodstream, despite it not yet being FDA-approved. The test has shown promise in clinical trials and could significantly improve early cancer detection, but some health systems remain cautious due to concerns about accuracy, cost, and regulatory approval.

via Chicago Tribune|
#blood-test#cancer-detection#early-diagnosis
"Challenges to Grail's Galleri Cancer Liquid Biopsy Evaluation Plan"
healthscience2 years ago

"Challenges to Grail's Galleri Cancer Liquid Biopsy Evaluation Plan"

WHO scientists are questioning the clinical trial endpoint being used by Grail to evaluate its Galleri blood test, which aims to detect multiple types of tumors early. The test is currently available in the U.S. but not yet approved by the FDA or reimbursed by Medicare, and Grail generated $30 million in revenue in the fourth quarter of 2023 while incurring a $197 million loss. If successful, the Galleri test could revolutionize cancer screening as a multi-cancer early detection test, but concerns about its evaluation process persist.

via STAT|
#cancer-screening#clinical-trial#galleri
"Grail's Multi-Cancer Blood Test Shows Promise in Large Study"
healthcare-technology2 years ago

"Grail's Multi-Cancer Blood Test Shows Promise in Large Study"

Grail, a blood testing company, presented the results of a large study at ASCO23, which showed that its commercial blood test, Galleri, could be used to diagnose patients suspected of having cancer due to symptoms such as abdominal pain, rectal bleeding, or unexplained weight loss. The test searches for the genetic fingerprints of cancer in the blood, and Grail hopes that doctors will consider it as an alternative to expensive scans or invasive biopsies.

via Endpoints News|
#asco23#blood-test#cancer-diagnosis